Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-26T03:39:27.772Z Has data issue: false hasContentIssue false

P-169 - Adjuvant Treatment in Bipolar Disorder

Published online by Cambridge University Press:  15 April 2020

R. Djebbi
Affiliation:
Razi Hospital, Mannouba, Tunisia
N. Bannour
Affiliation:
Razi Hospital, Mannouba, Tunisia
H. Elloumi
Affiliation:
Razi Hospital, Mannouba, Tunisia
W. Cherif
Affiliation:
Razi Hospital, Mannouba, Tunisia
R. Ghachem
Affiliation:
Razi Hospital, Mannouba, Tunisia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

The use of monotherapy with mood stabilisers during bipolar disorder concerns only few patients. Neuroleptics, benzodiazepines and recently the new-generation antipsychotic molecules are widely used as adjuvant therapy to mood stabilizers, indeed beyond the indications held by the guidelines.

Objectives

Modalities of prescription of psychotropic medication during the first admission and over a three-year follow-up in subjects with bipolar disorder.

Aims

Evaluate the adequacy of prescribing practices in naturalistic conditions and international guidelines.

Methods

Retrospective study of all first-admitted patients with bipolar disorder in two psychiatric wards of Razi Hospital between 2006 and 2008 and over a three-year follow-up.

Results

Our sample consisted of 72 patients. Over 80% of patients had initially received an incisive antipsychotic drug in combination with mood stabilizer; it was a conventional antipsychotic in 65.3%. Sedative neuroleptics were prescribed in 40.3% of cases with a duration average of 19.21 ± 11.97 months. The combination of two antipsychotic drugs was found in 33.3% of patients. The most frequent association was “haloperidol-chlorpromazine” (79%). Benzodiazepines were prescribed in acute phase in the majority of the sample (94%) with a duration average of 27 mo is ±8.4 months; it was the lorazepam in 70.6%.

Conclusions

Theoretical recommendations do not always reflect the practical situations. Evaluating indications and conditions of polytherapy are critical issues in future studies on the biological treatment of bipolar disorder.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2012
Submit a response

Comments

No Comments have been published for this article.